Product image of Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic) supplied by GNH India

Influvac

Active Ingredient:
Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic
Origin:
EU

Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

influenza virus vaccine, the active ingredient in Influvac, is an inactivated influenza vaccine presented as a solution for injection for intramuscular, subcutaneous use. It prevents influenza infection caused by influenza A and B viruses in individuals at risk.

GNH India supplies Influvac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Oy

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Influvac is an inactivated influenza vaccine used to prevent infection by influenza A and B viruses.

  • Seasonal Influenza: provides active immunity to reduce the risk of contracting flu during the annual season.
  • Children (≥6 months): protects young patients from influenza‑related illness.
  • High‑Risk Groups: lowers the chance of severe complications in people with chronic medical conditions.

How It Works

  • Influvac contains inactivated influenza virus antigens that stimulate the immune system to produce antibodies against the hemagglutinin and neuraminidase proteins of influenza A and B strains. The generated antibodies recognize and neutralize the virus upon exposure, conferring active immunity without causing disease.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the site of administration.
  • Redness or swelling: localized erythema or edema that resolves within a few days.
  • Low‑grade fever: transient temperature rise often accompanied by mild headache or muscle aches.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder that may develop weeks after vaccination.
  • Seizures: infrequent occurrence, particularly in children with a history of febrile seizures.

Precautions & Warnings

Influvac should be administered after careful assessment of the individual's medical history.

  • Allergy assessment: avoid if the patient has a severe allergic reaction to any vaccine component.
  • Guillain‑Barré history: evaluate risk and consider alternative protection strategies.
  • Pregnancy: safety data are limited; use only if the potential benefit outweighs the risk.
  • Immunocompromised patients: vaccine may elicit a reduced immune response; monitor effectiveness.
  • Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccines may interact with other agents that affect immune function.

Major Interactions (Avoid)

  • Live vaccines: do not administer concurrently with live attenuated vaccines.
  • Immunoglobulins or blood products: may diminish vaccine‑induced immunity if given within 3 months.
  • Antiviral therapy (e.g., oseltamivir) started within 48 h of vaccination: can reduce antibody response.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive drugs: monitor serologic response as efficacy may be lowered.
  • Antipyretics taken before vaccination: may blunt the immune response; advise use after injection if needed.
  • Other injectable vaccines given same day: observe for additive local or systemic reactions.

Frequently Asked Questions

Influvac is an inactivated influenza vaccine indicated for the prevention of influenza infection caused by influenza A and B viruses. It is administered to individuals, including children, adults, and high‑risk groups, to reduce the likelihood of seasonal flu and its complications.

The vaccine contains killed influenza virus antigens that stimulate the immune system to produce antibodies against the hemagglutinin and neuraminidase proteins of the virus. These antibodies recognize and neutralize the virus if the person is later exposed, providing active immunity without causing disease.

The specific dose and schedule of Influvac are determined by the prescribing healthcare professional based on age, health status, and local immunization guidelines. The prescriber will select the appropriate volume and route for each patient.

Safety data for Influvac in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should consult their physician before vaccination.

To order Influvac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and provide pricing, availability, shipping details (including cold‑chain handling), and any necessary import documentation.

Influvac is an inactivated, trivalent vaccine containing specific strains of influenza A and B, similar to other licensed seasonal flu vaccines. Compared with live‑attenuated or recombinant vaccines, it does not contain live virus and is suitable for a broader range of patients, including those with weakened immune systems, though efficacy may vary by strain match.

Influvac must be stored in a refrigerator at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Influvac is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via the intramuscular or subcutaneous route, typically into the deltoid muscle. The injection technique follows standard aseptic procedures.

The most serious risks include severe allergic reactions such as anaphylaxis and rare neurological events like Guillain‑Barré syndrome. Patients should be observed for at least 15 minutes after vaccination, and any signs of a serious reaction should be treated promptly.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a previous severe reaction to an influenza vaccine, should not receive Influvac. Additionally, persons with a recent history of Guillain‑Barré syndrome should discuss risks with their healthcare provider before vaccination.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT